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The main message of this review can be summarized as follows: aging and longevity, as complex traits having a significant genetic component,
likely depend on a number of nuclear gene variants interacting with mtDNAvariability both inherited and somatic. We reviewed the data available
in the literature with particular attention to human longevity, and argued that what we hypothesize for aging and longevity could have a more
general relevance and be extended to other age-related complex traits such as Alzheimer's and Parkinson's diseases. The genetics which emerges
for complex traits, including aging and longevity, is thus even more complicated than previously thought, as epistatic interactions between nuclear
gene polymorphisms and mtDNA variability (both somatic and inherited) as well as between mtDNA somatic mutations (tissue specific) and
mtDNA inherited variants (haplogroups and sub-haplogroups) must be considered as additional players capable of explaining a part of the aging
and longevity phenotype. To test this hypothesis is one of the main challenge in the genetics of aging and longevity in the next future.
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Mitochondrial loss of function is considered a common
feature in aging. Much less is known about the role of
mitochondria in longevity, that is the capability of an organism
to reach the extreme limits of the species-specific lifespan.
Mitochondria are deeply involved in ATP synthesis, heat
production, radical oxygen species (ROS) generation, fatty
acid and steroid metabolism and apoptosis, among others. Thus,
it is quite likely that dysfunction in mitochondrial metabolism⁎ Corresponding author. Department of Experimental Pathology, University of
Bologna, via S. Giacomo 12, 40126 Bologna, Italy. Tel.: +39 051 2094743; fax:
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doi:10.1016/j.bbabio.2006.05.040can, to some extent, be a cause of aging and, consequently, that
mitochondrial determinants of aging can in turn be detrimental
for longevity. Nevertheless, besides mitochondrial metabolism,
a number of other hypotheses have been presented that link
mitochondria and longevity through different mechanisms. In
particular, a special attention is presently devoted to mitochon-
drial DNA (mtDNA), on the basis of several lines of evidence.
First, mtDNA is maternally inherited, and heritability estimates
for lifespan based on offspring–mother regressions are higher
than those based on offspring–father regressions [1]. Second,
many inherited variants of mtDNA do exist, that are geographi-
cally distributed, and some of them have been described to be
associated with common complex traits [2] including longevity
[3–6]. Third, from bioinformatics analysis it appears that
number and length of direct repeat pairs in the mtDNAmolecule
constrain lifespan in long-living mammalian species [7]. Last
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information outside the nucleus and it is much more exposed
to mutagenic events than the nuclear DNA (nDNA). According
to the mitochondrial theory of aging, progressive accumulation
of somatic mutations leads to a decline in mitochondrial
function; therefore, the cell capability to counteract mtDNA
somatic mutations may play a positive role in the age-related
mitochondrial decline and thus in longevity [8].
In this review, we will focus our attention on data and
hypotheses linking mtDNA and longevity in humans, and we
will critically discuss the experimental models actually exploited
to get insight in this subject, as well as their pros and cons.
Finally, we will introduce an ongoing research project that
should, in part, allow us to overcome such problems and to
answer some questions on this topic. This project is named
GEHA, as an acronym of “Genetics of Healthy Aging”, and it is
supported by the FP6 of the European Commission (FP6-
503270).
2. mtDNA abundance
Human mtDNA is a 16,569 bp double-stranded, circular ge-
nome. In each cell several hundreds to thousands mtDNA
copies are present [9,10], and it is estimated that mtDNA
accounts for 0.15 to 2.2% of the mass of the cellular diploid
genome [11,12]. MtDNA is packaged into protein–DNA
complexes, called mitochondrial nucleoids (mt nucleoids) that
look like globular foci in human cells [13]. Among the proteins
discovered to interact with mtDNA in mt nucleoids, there are a
number of proteins involved in mtDNA replication and
transcription, among which TFAM, Twinkle, mtSSB, polymer-
ase gamma, BRCA1, PRSS15 (LON) are included (for a review,
see [14]). Contrasting data are reported about the age-related
changes in the copy number of mtDNA in both rodents and
humans. In some cases mtDNA copies have been found to be
increased during aging [15,16], while in other cases this number
has been found to be decreased [17–21] or unaltered [10,12].
Such contrasting data may be due to the different methods used
to quantify the amount of mtDNA (Real-Time PCR, Slot Blot)
and, more importantly, to a marked tissue specificity. On the
whole, no general consensus has been reached on the age-
related changes of mtDNA content. Accordingly, several
conceptualizations have been proposed to interpret these
conflicting data: a lack of changes in mtDNA amount may
reflect the incessant need of oxidative metabolism in tissues
such as myocardium, while an increase in mtDNA copy number
may be accounted for by a compensatory mechanism to
counteract the age-related accumulation of mutated/deleted
form of mtDNA [10,12,15,16]. For instance, it has been
reported that deleted mtDNA replicates much faster than intact
mtDNA [22]. On the other side, a decrease in mtDNA amount
might mirror the decreased oxidative capacities of the aged
tissues, such as liver and some skeletal muscles [17,18,20]. This
contradictory scenario is even more complicated when
considering the ratio between mtDNA copy number and the
relative abundance of mt nucleoid proteins, such as TFAM, that
has important roles not only in mtDNA packaging but alsotranscription [23]. Indeed, the amount of TFAM associated with
mtDNA may vary depending on cell type (reviewed by Chen
and Butow, [14]), while during aging, TFAM mRNA and
protein have been reported to be either increased [24] or
unaltered [18]. Furthermore, a lack of correlation between the
amount of mtDNA and mtRNA and mitochondrial polypeptides
has been reported [9,17,25,26]. A deeper discussion of the
complex relationship between mtDNA, packaging/transcription
proteins and translated polypeptides is outside the scope of this
review, but, whatever the meaning of age-related changes in
mtDNA abundance can be, it is conceivable that a preserved
capability to maintain a number of intact (non mutated) mtDNA
copies can impinge upon aging and longevity. Data on accepted
models of human longevity, such as centenarians, are still
lacking. However, it has to be stressed that the above mentioned
tissue-specific diversity in mtDNA abundance is likely a crucial
point to be considered when addressing these studies. In
particular, a different degree of age-related mosaicism has to be
expected in different tissues from old people, likely depending
on the need of energy supply, and thus comprehensive studies
performed on a number of representative tissues have to be
envisaged to draw meaningful results.
3. MtDNA somatic mutations
Because of its vicinity with ROS source (electron transport
chain) and the presence of an incomplete repair system, mtDNA
shows a high mutation rate. Mutated and wild-type mtDNA
molecules can coexist within the same cell, tissue or organ, and
this condition is called heteroplasmy. Cells containing only one
type of mtDNA (mutated or wild-type) are indicated as
homoplasmic [27]. However, the concept of homoplasmy is
more apparent than real: indeed, because of clonal expansion,
new mutations arising from random errors in mtDNA replica-
tion may occur at a variable level within cells and tissues, thus
remaining undetected in tissue homogenates and blood buffy
coats. In other words, heteroplasmy is detectable only if it
occurs above a threshold whose level depends on tissue type,
ROS production and stochastic factors. Although heteroplasmy
is usually observed in post-mitotic tissues characterized by high
energy demand, such as brain and skeletal muscle (for a review,
see [28]), mtDNA mutations accumulate also in dividing cells,
including stem cells [29,30].
The available literature suggests that a variety of deletions
and mutations accumulate with age in mtDNA (see [28]
Chomyn and Attardi, 2003). However, several important
questions are still unanswered. The most important one regards
the level of deletions/mutations attained in different cell types,
tissues and organs during aging. Strictly correlated to this
question is their functional importance, as it is believed that a
critical threshold of deletions/accumulations must be attained in
order to have functional consequences. The problem is further
complicated by the fact that the different organs and tissues of
the human body present a large difference regarding prolif-
erative activity, apoptotic rate and cell renewal, abundance of
stem cells, ROS production and mtDNA repair capability,
among others. All these differences can likely have a strong
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replication rate, accumulation of mutations) and thus the overall
scenario is extremely complex and best characterized by a
mosaic model where the rate of aging, mtDNA mutation
accumulation and dysfunction display a wide range of
variability. Assuming, as we will argue later, that mtDNA
mutations interact with nDNA genes and polymorphisms, as
well as with inherited mtDNA variants (haplogroups), and
taking into account the individual variability of both nuclear and
mitochondrial genomes, we can have an idea of the enormous
complexity posed by the involvement of mtDNA into a
complex trait such as longevity. In any case, the correlation
between level of mtDNA heteroplasmy, aging and longevity in
the different cells, tissues and organs of the body is still debated.
Recently, the fact that the accumulation of mtDNA mutations is
a cause rather than an effect of aging has been addressed by
experiments on a murine model, in which animals expressing a
proofreading-deficient version of the mtDNA polymerase
gamma accumulate mtDNA mutations and display features of
accelerated aging [31,32]. The mechanism by which such an
accumulation of mutations in mtDNA induces an aged
phenotype is still controversial, but it appears that unexpectedly
no increased oxidative stress occurs in such mtDNA mutator
mice [32,33]. Different hypotheses have been proposed to
explain the observed phenotype, from progressive defects in
respiratory function to increase in apoptosis, and lately to
depletion of stem cells [34]. However, a major pitfall of this
experimental model is that it does not really mimic natural
aging, but it is rather to be considered as a sort of genetic
“disease” with progeroid features. In this specific case an
exhaustion of stem cells could be the end result of the mtDNA
mutator phenotype. This is suggested by the fact that the
Authors found that the tissues mostly affected in such mouse
model are those which actively proliferate (testis, thymus,
intestine, blood), but not the post-mitotic ones (brain), as it is
expected for normal aging. Again, the rate of mtDNA mutations
reached in these mutator mice is much higher than that found in
normally aged mice, and the observed effects are much larger
and precocious than expected. On the whole, although the
mouse model of accelerated aging provides strong evidence that
mtDNA mutations can contribute to aging, further experimental
studies are needed to confirm that such mutations are causative
to aging and involved in longevity. This argument can be
generalized, and in particular many gerontologists, including
ourselves, think that models of increased longevity are to be
preferred to models in which shorter lifespan is produced by
genetic manipulations in a variety of organisms, from
nematodes to mammals. These models are more complicated
and more demanding but they represent the most interesting
challenge in this field. The best examples of genes causally
involved in aging and longevity are provided by non-
mitochondrial genes such as klotho and lin-4 which cause
accelerated aging when mutated and which extend lifespan
when over-expressed in mouse and C. elegans, respectively
[35–37]. We are far from this type of situation in humans, and
particularly in mtDNA, where studies on this topic are still in
their infancy. However, it can be assumed that the capability tomaintain mtDNA integrity and to avoid the accumulation of
mtDNA mutations is likely a feature of longevity. To critically
evaluate the informative capability of mouse models of
accelerated aging as far as the role of the accumulation of
mtDNA mutations, a comparison between polymerase gamma
mutator mice, normal aged mice and long living humans is here
proposed as far as their hematopoietic capability. The mutator
mice are profoundly anemic [32], likely as a result of stem cells
exhaustion, while normal aged mice are not anemic [38], and
thus it is possible that in normal aged mice mtDNA mutations
do not accumulate to such an extent capable of inducing stem
cell depletion and consequent anemia. As far as humans are
concerned, prevalence of anemia in persons 85 years and older
is 26% in males and 20% in females (one third of the cases
being due to nutritional deficiencies) and is associated with
frailty and increased morbidity, disability and mortality [39,40].
Thus, the majority of older persons do not suffer of anemia,
which still remains a major problem in the elderly. Our studies
on centenarians also suggest that they are not anemic, thus
indicating that their hematopoietic capability is quite preserved
[41,42]. This in turn would support the hypothesis that in long-
living people, hematopoietic progenitor cells, and likely their
mtDNA integrity, is well preserved. Indeed, in healthy
centenarians classified according to [43] we found a well
preserved capability of circulating CD34+ cells to respond to
hematopoietic cytokines and to form erythroid, granulocyte-
macrophagic and mixed colonies in a way indistinguishable
(number, size and morphology) from that of young subjects,
despite their reduced absolute number [42]. These results have
been recently replicated [44]. At present, no direct data
regarding mtDNA mutations in long-living people and
centenarians are available, and this topic deserves a specific
attention in the next future. It is clear that such mice models are
exaggeration of normal aging phenotypes, and that any
extrapolation to the situation of non genetically manipulated
animals, and particularly of humans, is premature.
4. Deleterious or beneficial? The special case of C150T
mtDNA mutation
All the arguments discussed above are characterized by the
implicit assumption that all mtDNA mutations are deleterious
by definition and fully explain the phenotype by themselves. We
challenge this tenet on the basis of recent data regarding the
accumulation of a specific mtDNA mutation we obtained in
centenarians. At least in theory, there is no a priori reason to
consider any mtDNA mutation as detrimental. A mtDNA
mutation might increase survival only at later ages, in the post-
reproductive period, or increase the survival of a subject in
earlier periods of life. This may be the case of a specific mtDNA
mutation we described quite recently [45]. This mutation is a C
to T transition found at position 150 of mtDNA control region
(CR) and it is found to be over-represented in centenarians with
respect to young and old people in Italian population [45]. This
mutation likely changes the origin of replication of the mtDNA
heavy strand at position 149, substituting for that at position
151. Age-related mutations in mtDNA CR usually show a tissue
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C150T mutation was found in three different cell types, i.e.,
peripheral blood lymphocytes, granulocytes and fibroblasts. An
intriguing characteristic of these mtDNA CRmutations is that in
some cases they appear to be inherited mtDNA polymorphisms.
The available data indicate that, on some occasions, the C150T
mutation is undoubtedly the result of a somatic event, as
suggested by its absence in fibroblasts derived from biopsy of
adult subjects and its presence from a second biopsy taken 10
years later from the same subjects. On the other side, the
possibility that C150T can also be an inherited polymorphism is
indicated by the fact that this mutation has been found to be
present at high frequency in both members of monozygotic and
dizygotic twin pairs, also suggesting that it likely confers a
selective advantage earlier in life (possibly during pregnancy)
[45]. It is interesting to note that the C150T mutation has been
found to be associated with longevity in three additional
populations, such as Irish, Finnish and Japanese [6,46]. Thus,
C150T might be advantageous throughout life as an inherited
polymorphism or contributing to longevity as somatic mutation
arising later in life. The above mentioned circumstantial
evidence indicate that C150T mutation/polymorphism likely
confers an advantage for survival, but the mechanism is still
unclear. The following non-mutual hypotheses can be put
forward: first of all, as originally suggested in our paper [45],
the C150T mutation could confer a replicative advantage to the
mtDNA, thus accounting for the homoplasmic or nearly
homoplasmic level mostly found in cells from centenarians.
Second, the C150T mutation might be related to the cellular
origin of the mtDNA used in our study, i.e., lymphocytes and
granulocytes [45] and to immunosenescence [47]. Indeed, the
accumulation of megaclones of memory T lymphocytes, and
their filling of the immunological space, concomitant with the
exhaustion of naïve T cells, is one of the most important marker
of immunosenescence and is correlated with morbidity and
mortality in the elderly [48,49]. Third, the C150T mutation
could confer a resistance to oxidative stress and apoptosis, and
this topic is under scrutiny in our laboratories with the use of
appropriate cybrids.
5. MtDNA repair systems and longevity
The preservation of mtDNA integrity requires efficient
detoxifying and repair systems. As far as detoxifying systems,
two studies have been performed in Italian centenarians that
investigated a possible association between superoxide-dismu-
tase 2 (SOD2) gene variability and longevity. The first study,
which considered only genetic data (allele and genotype
frequencies), was not able to reveal any significant association
[50]. However, when the same gene dataset was implemented
by demographic data, a significant gene-environment interac-
tion was observed by SOD2 allele T in modulating lifespan
[51]. This type of study also suggests that sophisticated
algorithms which integrate genetic and demographic data are
needed to explore the subtle interactions between gene
variability and lifespan [52]. Therefore, it cannot be excluded
that other genes involved in ROS scavenging and antioxidantsystems can be associated, alone or in combination, to
longevity. A recent paper has shed some light on this complex
topic. In particular, the role of ROS in mammalian longevity has
been addressed by the generation of transgenic mice over-
expressing human catalase localized to the peroxysomes, the
nucleus or the mitochondria [53]. Median and maximum life
span were maximally increased of about 5 months in mice
where catalase was targeted to mitochondria. It is interesting to
note that in these mice a mild reduction of oxidative stress and
damage was observed in tissues such as skeletal muscle and
heart, as well as the reduction of mtDNA deletions. However,
this last finding was evident in mice at 18–22 months of age and
only in skeletal muscle, and the difference between wild type
and transgenic mice was no more evident in older mice
(33 months of age) in both skeletal muscle and heart. Thus, the
possible causative role of the accumulation of mtDNA deletions
in this model of lifespan extension is still unclear. Moreover, a
different sensitivity of skeletal muscle and heart is also evident
in this model, and skeletal muscle appears to be more sensitive
to the beneficial effects of catalase over-expression. The
Authors also comment their data regarding a possible diluting
effect on catalase over-expression in mitochondria due to
changes in the overall genetic background in successive
generations of the transgenic mice. While rendering unclear
some of the above mentioned results, this comment stresses
once again the importance of the genetic context represented by
the nuclear genome on mitochondrial function and mtDNA
physiopathology. On the whole, these data further support the
importance of mitochondria as a source of ROS and as a
limiting factor in determining mammalian longevity.
As far as mtDNA repair systems, it has been recently
reported that the base-excision repair (BER) activity is
decreased in brain areas of aged mice [54]. It is possible that
allelic variants of genes involved in BER system can confer
different efficiency in mtDNA repair activity, and thus are
putative longevity genes. Thus, such allelic variants are
expected to be over-represented in long-living people and
centenarians. We are currently testing this hypothesis in genetic
association case-control studies in an Italian population
(centenarians and young subjects). It has been reported that
also p53, one of the pivotal players of nDNA repair can
participate in mtDNA BER [55], likely through a physical
interaction with polymerase gamma [56]. This interaction
would increase polymerase gamma activity. It is known that
p53 carries a common polymorphism at codon 72, that yields
an Arginine-to-Proline aminoacidic substitution. The two
resulting isoforms of p53 have, among other biological
differences, a different capability to localize at the mitochon-
drial level [57]. It would be interesting to investigate whether
subjects with different genotype of p53 are characterized by a
different level of polymerase gamma activity and of mtDNA
instability. This would be of great interest, since p53 codon 72
genotype has also been observed to modulate mortality by
cancer and longevity in a study of Dutch nonagenarians [58]. It
is remarkable that these results are apparently different from
those obtained in other populations, thus suggesting a complex
interaction between p53 polymorphisms and longevity [59].
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Besides somatic mutations, mtDNA is characterized also by a
series of inherited sequence point mutations that define a variety
of haplotypes firstly described by the group of Wallace [60].
Phylogenetically related haplotypes are grouped together to
form haplogroups that display a region-specific distribution
[61–63].
The classification of mtDNA haplogroups is based on
information gained from RFLP analysis of the coding region
[64]. Haplogroups are coded with capital letters and subclusters
with a running number. Three African (L1, L2, L3), seven Asian
(C, D, G, E, A, B, F) [65], and nine European (H, T, U, V,W, X, J,
I, K) [64] main mtDNA haplogroups were identified. This
research field is rapidly growing, and new sub-haplogroups are
continuously emerging [66]. For instance, a recent paper
reported that haplogroup H, the most common in Europe, can
be subdivided into at least 15 sub-haplogroups [67], and
formerly haplogroup K has been lately recognized as a sub-
haplogroup of haplogroup U. To provide a comprehensive
description of these haplogroups and subhaplogroups is outside
the scope of this review. What it is interesting to us is that these
variants are likely non neutral, and in particular a series of
experimental evidence have been published suggesting that
some mtDNA haplogroups are associated with longevity [3–
5,46], as well as with mitochondrial diseases [68,69], and
complex diseases [2]. In particular, in Caucasians such as
northern Italians, haplogroup J is over-represented in long-living
people and centenarians [4] thus suggesting a role for this
mtDNAvariant in longevity. In such study, both male and female
centenarians were analyzed, but haplogroup J was over-
represented only in male centenarians. This gender difference
is quite common in studies on the genetics of longevity, where
different polymorphisms of nuclear genes have been found to be
associated with longevity only in males or females. Most of the
positive correlations between nuclear gene polymorphisms and
longevity we described regard male centenarians. The reason for
such a gender difference is not clear, but it can be related to the
fact that male centenarians are more selected, being less
represented in the general population and having a lower
probability to reach a hundred years of age in comparison to
females. Accordingly, it can be speculated that males rely more
upon genetics, either nuclear or mitochondrial, to attain
longevity. In any case, such a male-specific connection between
mtDNA haplogroups and longevity fits with the hypothesis that
mtDNAvariations have a higher impact on male than on female
longevity [70]. This gender difference could be one of the
consequences of the maternal inheritance of mtDNA, which in
turn implies a higher relaxation and less purging of male-specific
mitochondrial phenotype, being males evolutionary dead ends
for mtDNA.
The over-representation of haplogroup J in nonagenarians
and centenarians has been replicated in Irish and Finnish long-
living people [5,46], but not in southern Italians [71]. Indeed,
when a large population (883 subjects with age from 18 to
108 years) from southern Italy was analyzed for the association
of haplogroup J with longevity, no positive signal was found,suggesting that in such a population haplogroup J per se does not
contribute to longevity. On the other hand, in Finnish population,
mtDNAmutations characteristic of J2 subhaplogroup (489C and
10398G) modified the association between the 150T mutation
and longevity [6]. On the whole, these results support the idea
that the effect of mtDNA inherited variants on longevity is
geographically/population dependent.
7. MtDNA inherited variants and age-related diseases
MtDNA variants have been studied in a variety of diseases,
including neuromuscular and neurodegenerative diseases,
diabetes, cancer and sepsis (see for example [72–76]). Here
we will discuss only the data available on two major
neurodegenerative diseases associated with aging, such as
Parkinson's and Alzheimer's Diseases, where several studies
have been reported. For more a comprehensive review of other
diseases, the reader is referred to a recent review by Wallace [2].
As far as Parkinson's Disease (PD), haplogroup J and
subhaplogroup K have been found to be under-represented in
patients with PD [77]. These results are in line with those
obtained in an Italian population [78], and in an English
population [79]. Other studies suggested an increased risk of PD
with haplogroups clusters such as JT [80] and JTIWX [81].
Contrasting data are reported as far as Alzheimer's Disease
(AD) is concerned. In particular, it has been reported that
haplogroup T is under-represented in AD patients, while
haplogroup J seems to be over-represented in AD patients
[82]. Haplogroup U has been reported to be under-represented in
females and over-represented in males Caucasian AD patients
[83]. On the other side, it is to note that several studies did not
find any association between mtDNA haplogroups and AD by
studying different Caucasian populations [79,84–86]. On the
whole, no general consensus has been reached as far as the
correlation between mtDNA haplogroups and AD. These results
are summarized in Table 1.
8. LHON as a paradigm of the role of mtDNA in complex
traits
LHON is one of the best studied mitochondrial diseases, and
most cases are associated with one of three mtDNA point
mutations (G11778A, G3460A, and T14484C) affecting genes
encoding complex I (NADH:ubiquinone oxidoreductase) sub-
units, and currently regarded as pathogenic. Despite the fact that
all these mutations are homoplasmic in the large majority of
families, the severity of the disease can be quite variable and
gender-biased [87], suggesting that additional genetic compo-
nents must be involved in order to explain the different
penetrance of the mtDNA mutations. A key observation has
been reported by Torroni et al. who found that LHON is
associated with mtDNA haplogroup J [68], and this observation
has been confirmed by other Authors [69,88]. Recently, it has
been argued that the clinical heterogeneity of LHON can be also
explained by assuming the critical role of an interaction between
the mitochondrial mutations and a second nuclear gene, both
necessary to explain the pathological effect of mtDNAmutations
Table 1
Studies on mtDNA haplogroups and complex traits (longevity, Parkinson's
disease and Alzheimer's disease)
Complex
trait
No. of cases
vs. controls
Results Ethnicity Reference
Longevity 37 vs. 252 Over-represented: D Asiatics [3]
109 vs. 125 Over-represented: J Northern
Italian
(males)
[4]
129 vs. 100 Over-represented: J Northern
Irish
[46]
225 vs. 657 Over-represented: J andU,
Under-represented: H
Finnish [5]
155 vs. 728 No association Southern
Italian
[71]
Parkinson's
disease
609 vs. 340 Under-represented: J
and K
Caucasians [77]
90 vs. 129 Over-represented: J+T Northern
Irish
[80]
238 vs. 183 Over-represented:
J+T+I+W+X
Finnish [81]
620 vs. 1995 Under-represented: K Italians [78]
455 vs. 447 Under-represented:
U+K+J+T
English [79]
Alzheimer's
disease
69 vs. 83 Under-represented: T
Over- represented: J
French-
Canadian
[82]
185 vs. 179 No association English [84]
644 vs. 180 Under-represented: U Caucasian
females
[83]
345 vs. 148 Over-represented: U Caucasian
males
[83]
190 vs. 340 No association Old Order
Amish
[85]
185 vs. 447 No association English [79]
75 vs. 64 No association US
Americans;
[86]
70 vs. 64 No association English
MtDNA haplogroups and/or clusters having higher frequency in cases than
controls (over-represented) are considered to have a positive association with the
trait, while those under-represented are considered to have a negative association
with the trait. D, H, I, J, K, T, U, W, X refer to haplogroup nomenclature as
reported in MITOMAP (http://www.mitomap.org/).
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se, but it contributes to the pathogenic effect of themitochondrial
mutations [89].
This observation on LHON suggests that, even when the
mtDNA mutations characteristic of the disease are homo-
plasmic, they are insufficient per se to fully explain the
phenotype, and suggests that similar interactions within the
mtDNA itself (mtDNA mutations plus mtDNA haplogroups
and subhaplogroups) and between the mtDNA and nDNA
(nuclear–mitochondrial cross-talk) might occur in other
conditions where mtDNA is involved, including aging and
longevity.
9. MtDNA variants and mitochondrial functions: an open
field of research
On the whole, a series of circumstantial evidence suggest
that the different mtDNA lineages are qualitatively different
from each other, bearing mutations that can modulate themitochondrial function, and consequently influence longevity
as well as diseases. It has been proposed that the observed
geographic distribution of mtDNA lineages resulted from
selection mainly driven by adaptation to climate and nutrition
(the type of available food) [67,90]. However, the mechanism
by which these haplogroups can impinge upon longevity and
diseases is far from being clear. Few papers report that
haplogroups confer a different biochemical activity to mito-
chondria. For example, it has been reported that haplogroups H
and T display a significant difference in the activity of
OXPHOS complexes I and IV [91]. These results can be
accounted for by the possibility that non-synonymous sequence
variations present in haplogroups and sub-haplogroups that can
modulate mitochondrial activity do exist. In fact, it has been
observed that some haplogroups that are more frequent in
temperate and arctic areas contain very well conserved
aminoacid variants that lie in coding genes, such as ND2,
ND4, and Cyt b (see [90]), and it has been suggested that these
aminoacid changes can modify the efficiency of electron
transport chain, thus shifting mitochondrial activity towards
an increased production of heat. Similarly, it could be
hypothesized that such mtDNA-based modifications of mito-
chondrial activity can also impinge upon longevity by resulting
in a reduction in OXPHOS efficiency, which in turn would
reduce mitochondrial ROS stress and decrease apoptosis [44].
This hypothesis fits with some of the above mentioned mouse
models of increased longevity attained by over-expression of
catalase in mitochondria and with the major role of apoptosis in
provoking the accelerated aging phenotype in mitochondrial
polymerase gamma mutator mice. However, it is likely that in
most cases the functional difference between mtDNA hap-
logroups is more subtle and relies upon more complex
relationships between nuclear and mitochondrial genomes.
10. Nuclear–mitochondrial interactions
The nucleus and the mitochondria interact in a variety of
physiological functions that are crucial for cell activity and
survival. Different levels of interactions and cross-talk between
nucleus and mitochondria can be envisaged:
(i) the first is a major topic of proteomics and it is based on
the fact that, during evolution, most of the original
information encoded in mitochondrial genome translo-
cated to the nucleus and thus the majority of structural
mitochondrial proteins are encoded by nuclear genes.
mtDNA encodes for only 13 of the more than 80 proteins
involved in the respiratory chain, while nDNA encodes
for all the remaining proteins. Moreover, the complete
mitochondrial proteome is estimated to about 1000–2000
different proteins [92], which are all nuclear-encoded in
order to perform the different mitochondrial functions,
resulting in a coordinated regulation of the two genetic
systems of the cell, crucial for cell physiology [93].
(ii) Another group of nuclear-encoded proteins localize to
mitochondria during important phenomena such as, for
example, apoptosis [94]. Indeed, the nucleus not only
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building up mitochondria (as reported above) but also
strongly regulates their activity. This is suggested by the
fact that an increasing amount of regulatory and adaptor
proteins is reported to have a secondary mitochondrial
localization, as already mentioned for p53 (see previous
paragraph and [55]) and p66shc [95].
(iii) Experimental data have been collected suggesting that a
third level of communication occurs regarding nuclear and
mitochondrial genomes. This finely tuned, nucleus-
mediated, regulation of mitochondrial activity requires
that the nucleus is constantly informed about the
functional status of mitochondria, in a classical feed-
back loop fashion. Thus, a crucial component of cell
signaling travels from mitochondria to the nucleus. This
mitochondria-to-nucleus signaling, called “retrograde
response” in yeast [96,97], provides information on the
state of mitochondria and can serve to adjust carbohydrate
and nitrogen metabolism [97]. Studies on model organ-
isms have revealed a connection between retrograde
response and modulators of aging such as ROS produc-
tion, ATP levels, altered nutrient levels, metabolic shift
resulting from changes in insulin and IGF-1 signaling
pathways [98,99].
We surmised that similar retrograde response does exist in
humans and impinges upon aging and longevity [100]. In
particular, we found genetic evidence of interactions between
specific mtDNA haplogroups and genes involved in human
longevity. A non-random association between mtDNA hap-
logroups and Tyrosine hydroxylase polymorphisms has been
found in aged people and centenarians but not in young people
[50]. Furthermore, we reported that frequency of the a3 allele of
HRAS1 3′ variable number tandem repeat (HRAS1 3′VNTR)
decreases in centenarians in respect to young people, and we
estimated thatduringaginga3carriershavean increasedmortality
risk and that the haplogroups K and U were significantly over-
represented in a3 allele carrier centenarians. No interaction
betweenHRAS1 3′VNTRa3 allele andmtDNAhaplogroupswas
found in young individuals [101].
A correlation was also reported between mtDNA hap-
logroups and APOE4 allele in relatively young AD patients,
where a significant protective effect of haplogroups U and K
in patients carrying the APOE4 allele was found [102]. At
variance, other Authors found that the effect of mtDNA
haplogroups on AD risk is independent of APOE status, and
a significant association of haplogroup U was only evident
when data were stratified by sex [83]. Probably these
differences can be explained by the geographic origin of the
samples used in the two studies. Preliminary results from our
lab in AD patients, while confirming the association between
mtDNA haplogroups and AD, do not suggest an interaction
between APOE4 genotypes and mtDNA haplogroups (Santoro
et al., unpublished data). Interestingly, the mean age of this
sample of AD patients was 16 years higher than that of the
samples analyzed by Carrieri and colleagues [102], and
comparable with those of van der Walt and colleagues [83].The lack of interaction between mtDNA haplogroups and
APOE gene variants could be due to a decreased risk effect of
APOE4 allele in advanced age. More investigations are
needed to clarify this topic.
On the whole, the few available data in humans are
compatible with the hypothesis that mtDNA haplogroups
could interact with nuclear gene variants and modulate their
penetrance. As far as we know a totally unexplored area in
humans is the predicted stronger interaction between mtDNA
polymorphisms and genes present in X chromosomes on the
basis of their maternal co-transmission. Indeed mtDNA and X
chromosomes are co-transmitted through females two-thirds of
the times, with a higher probability to maintain joint mito-
nuclear polymorphisms [70]. It is important to note the opposite
case of Y chromosome which is never co-transmitted with
mtDNA.
11. Nuclear–mitochondrial interactions: cybrids and new
in vivo models
In vitro and in vivo models have been proposed to
demonstrate that mtDNA inherited variants modulate biologi-
cal functions. The best known in vitro model is represented by
cytoplasmic hybrids. This technique allows the analysis of
mtDNA mutations or inherited variants by minimizing the
effect of the nuclear genome that is kept constant Box 1.
Cybrid cell lines are relatively easy to obtain and easy to
maintain (cells can be frozen and stored for years). This model
is largely used to test the effect of specific mtDNA mutations.
However, it has to be taken into account that it presents several
possible limitations due to the technique used to obtain cybrid
cells, that is, for example, culture in ethidium bromide,
treatment with polyethylene glycol, selective media, etc. (see
Box 2).
As far as in vivo models, an elegant approach has been
developed by Roubertoux and coworkers [103], and this model
appears to be particularly suitable to study the effect of
mtDNA inherited variants on mammalian complex traits. In
this model, the total, reciprocal substitution of mtDNA was
achieved by 20 repeated backcrosses in two mice strains which
differed for their nDNA as well as for their mtDNA
(intraspecific mtDNA crosses). The Authors demonstrated
that the substitution of mtDNA in such mice strains modified
learning, exploration, sensory development and the anatomy of
the brain with respect to parental strains, this effect becoming
particularly evident in aged mice. This model, while providing
additional evidence that mtDNA polymorphisms are not
neutral, gives evidence that they can modulate biological
functions and parameters, and suggests that interactions
between the two genomes (the mitochondrial and the nuclear
one), are particularly important for cognitive functions at
advanced age. This in vivo model is particularly suitable for
studies aimed to disentangle the role of and the interactions
between mtDNA inherited variability and nuclear genes on
mammalian longevity. The effect observed in short-living
mammals may be even more important in long-living
mammals such as humans whose life spans over decades. A
ox 1
echnical problems of studies on mtDNA mutations
nd variants
As for nuclear genes, when studying mtDNA
variants both in case-control analyses and in other
studies, stringent guidelines have to be followed in
order to avoid analysis bias (see table below).
Indeed, the inconsistency of the results could
often be due to methodological complexities or
limitations, and to mistakes in samples recruit-
ment and selection. On this last point, it must be
mentioned the deCODE study on Icelanders that
shows the presence of a notable regional subdivi-
sion in the Icelandic gene pool [105] This study
strongly supports the crucial importance of a
correct sampling to avoid false-positive results in
association studies. Recommendations for the
analysis of mtDNA variability:
1. To use an appropriate sample size, a task
becoming more and more demanding as the
resolution of the mtDNA variability increases.
2. To use a homogeneous population of cases and
controls,matched for sex, ethnicityandgeography.
3. To take into account the multifactorial nature of
aging and age related diseases, and the possible
interactionwith nuclear genes [106].
4. To avoid technical problems related to:
• non-accurate technique (necessity to check for
the amplification of nuclear pseudogene by
using an appropriate controls, e.g. ρ0 cells).
• possible sample contamination
• quantification of mtDNA heteroplasmy by
appropriate technique, e.g. DHPLC [107]
• to ascertain whether DNA is directly extracted
from cells/tissues or it derives from WGA
(whole genome amplification)
Another possible source of confounding results
is the occurrence of mtDNA recombination. In-
deed, the dogma that mtDNA does not recombine
has been recently broken. mtDNA recombination
has been described to occur at a cell level both in
vivo and in vitro [108,109]. Whether mtDNA
recombination is a common event in humans
remains to be determined. Indeed, there is only
little evidence that it can occur at population level
[110]. These findings have possible important
implications for mtDNA-related diseases, the inter-
pretation of human evolution and population
genetics and forensic analyses based on mtDNA
genotyping [109,110]. To better understand this
problem it could be useful to perform studies on
human pedigrees, which are probably the most
informative way to investigate this topic.
ox 2
YBRIDS: a method to study the interaction between
tDNA variants and the nuclear genome
Beside animal models, one of the most popular
and commonly used model for mtDNA study is
represented by cytoplasmic hybrids, or cybrids.
Developed by King et al. in Attardi's laboratory
[111], the technique relies on the creation of a
mtDNA-null (ρ
0
) cell from cancer cell lines by long
exposure to 3.8-diamino-5-ethyl-6-phenylphenan-
thridiniumbromide (EtBr) [112]. This intercalating
agent is toxic to the mitochondrial genome by
inhibiting mtDNA replication, while it is supposed
to have almost no effect on nDNA [113]. This
specificity is due to the the intercalation of EtBr into
mtDNA but not in nDNA, that is strictly packed as
chromatin. Recently it has been observed that
genetic instability occurs in cells upon mtDNA
depletion [114] and thus particular attention should
be devoted to possible chromosomal changes when
addressing the study of nuclear-mitochondrial cross
talk using cybrid cells. After creation of a ρ
0
cell line
which is completely depleted of mtDNA, a fusion of
enucleated cells with the ρ
0
cell is induced bymeans
of polyethylene glycol 1500. This produces a new
cell line in which the nDNA comes from the parental
ρ
0
cells, and the mtDNA comes from the donor cells
[115]. To select the cytoplasmic hybrids requires
several weeks of culture in selective uridine-free
medium containing pyruvate to sustain the true
cybrids and to eliminate ρ
0
cells. Moreover, if only
the faster growing colonies are picked up, a bias
could be created.
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arecent study in Drosophila that used an experimental design
similar to that of Roubertoux, but extended to interspecific
crosses, showed important epistatic interactions between
mtDNA and nDNA on longevity which were more evident
in interspecific introgression lines in comparison to intraspe-
cific lines [104]. Owing to these mitonuclear epistases the
quantitative effect of mtDNA variability on longevity might be
highly dependent on significant interactions with ubiquitous
nuclear allelic variation.
12. Conclusions
All the data considered in this review support the hypothesis
that mtDNA is involved in aging and longevity. A number of
different possible mechanisms have been proposed to explain
this involvement, from mtDNA abundance and accumulation
of somatic mutations, to inherited variability and cross-talk
with nuclear genome. The study of the precise role of mtDNA
in aging and longevity has been addressed using a variety of
experimental models, while the most part of studies involving
human subjects are genetic association studies. These latterB
C
m
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the ever increasing complexity of inherited lineages (hap-
logroups and sub-haplogroups), and to the relative tissue-
specific importance of mitochondria on the other side. To
overcome these pitfalls, it is necessary: i. to study a large
number of aged subjects; ii. to take into account technical tips;
iii. to study the entire sequence of mtDNA in order to consider
its whole complexity. To this end, in the framework of the
European Project “Genetics of Healthy Aging” (GEHA), an
unprecedented number of old subjects will be studied as far as
mtDNA sequence variation is concerned. In particular, 2,650
couples of sibs both older than 90 years of age as well as 2,650
young controls will be collected all along 11 European
Countries. We are confident that this study will be able to
provide important data on a large number of young and old
subjects belonging to different geographic origins, including
countries from southern and northern Europe.
Another important aim of the GEHA Project is to perform a
genome-wide analysis of the 2650 sib pairs in order to identify
candidate chromosomal regions which harbor longevity genes
and to perform more dense analysis in order to finally identify the
gene variants involved in the trait. Moreover, all subjects within
the GEHA Project will be studied for APOE variants (ε2, ε3, ε4),
assumed as the gold standard gene, whose variants have been
found associated with aging and longevity in all the studies. One
of the characteristics of the GEHA Project is to combine the data
which will emerge from the study of the nuclear genome with
those emerging from the study of the mitochondrial genome.
In conclusion, the main message of this review can be
summarized as follows: aging and longevity, as complex traits
having a significant genetic component, likely depend on many
nuclear gene variants interacting with mtDNA variability both
inherited and somatic. We also surmise that what we
hypothesize for aging and longevity could have a more general
relevance and be extended to other complex traits, such as age-
related diseases like cardiovascular diseases and diabetes,
besides AD and PD, where nDNA–mtDNA interactions as
well as mtDNA–mtDNA interactions can play a critical role.
The genetics which emerges for complex traits, including aging
and longevity, is thus even more complicated than previously
thought as mtDNA variants (both somatic mutations and
inherited variants) must be considered as additional players
capable of interacting with nDNA variants, thus possibly
explaining a part of the aging and longevity phenotype. To test
this hypothesis is one of the main challenge in the genetics of
aging and longevity in the next future.
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